Nature's TRAIL - On a path to cancer immunotherapy

被引：298

作者：

Smyth, MJ ^{[1
]}

Takeda, K

Hayakawa, Y

Peschon, JJ

van den Brink, MRM

Yagita, H

机构：

[1] Peter MacCallum Canc Inst, Canc Immunol Program, Sir Donald & Lady Trescowthick Labs, Melbourne, Vic 3002, Australia

[2] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan

[3] Immunex Corp, Seattle, WA 98101 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

来源：

IMMUNITY | 2003年 / 18卷 / 01期

关键词：

D O I：

10.1016/S1074-7613(02)00502-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The TNF-related apoptosis-inducing ligand (TRAIL) offers great promise as a cancer therapeutic. Initially, soluble recombinant versions of the TRAIL molecule have exhibited specific tumoricidal activity against a variety of tumors alone, or in combination with other cancer treatments, and much anticipation awaits the outcomes from early clinical trials. More recently, the natural role of TRAIL has been explored in tumor and allogeneic bone marrow transplantation models in the mouse. Strikingly, the TRAIL effector pathway appears a vital component of immunosurveillance of spontaneous or resident tumor cells by both T cells and NK cells, stimulating more hope that manipulating TRAIL activity is a natural path to improved cancer immunotherapy.

引用

页码：1 / 6

页数：6

共 37 条

[1] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[2] Death receptors: Signaling and modulation [J].

Ashkenazi, A ;

Dixit, VM .

SCIENCE, 1998, 281 (5381) :1305-1308

[3] TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].

Bodmer, JL ;

Holler, N ;

Reynard, S ;

Vinciguerra, P ;

Schneider, P ;

Juo, P ;

Blenis, J ;

Tschopp, J .

NATURE CELL BIOLOGY, 2000, 2 (04) :241-243

[4]

Burns TF, 2001, J BIOL CHEM, V276, P37879

[5] Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice [J].

Cretney, E ;

Takeda, K ;

Yagita, H ;

Glaccum, M ;

Peschon, JJ ;

Smyth, MJ .

JOURNAL OF IMMUNOLOGY, 2002, 168 (03) :1356-1361

[6] To die or not to die - the quest of the TRAIL receptors [J].

Degli-Esposti, M .

JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 65 (05) :535-542

[7] TRAIL-induced apoptosis requires Bax-dependent mitochondria release of Smac/DIABLO [J].

Deng, YB ;

Lin, YH ;

Wu, XW .

GENES & DEVELOPMENT, 2002, 16 (01) :33-45

[8] Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling [J].

El-Deiry, WS .

CELL DEATH AND DIFFERENTIATION, 2001, 8 (11) :1066-1075

[9] Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [J].

Fanger, NA ;

Maliszewski, CR ;

Schooley, K ;

Griffith, TS .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (08) :1155-1164

[10] Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL [J].

Griffith, TS ;

Wiley, SR ;

Kubin, MZ ;

Sedger, LM ;

Maliszewski, CR ;

Fanger, NA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (08) :1343-1353

← 1 2 3 4 →